Last reviewed · How we verify
QBS10072S
At a glance
| Generic name | QBS10072S |
|---|---|
| Sponsor | Patrick Wen, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Assessing QBS72S For Treating Brain Metastases (PHASE2)
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (PHASE2)
- A Phase IIa Study to Evaluate NBQ72S (PHASE2)
- Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QBS10072S CI brief — competitive landscape report
- QBS10072S updates RSS · CI watch RSS
- Patrick Wen, MD portfolio CI